Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3/Mesothelin CAR-γδT in Advanced Solid Tumors
NCT06196294Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- May 2024
- Primary completion
- Nov 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of glypican-3-chimeric antigen receptor-gamma delta T cells + mesothelin-chimeric antigen receptor-gamma delta T cells in pancreatic cancer (PC), lung cancer, liver cancer and 2 more (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Dose Limiting Toxicity at 6 months. Started May 2024; status: recruiting.
02
Drugs
glypican-3-chimeric antigen receptor-gamma delta T cells + mesothelin-chimeric antigen receptor-gamma delta T cells
03
Conditions
pancreatic cancer (PC)lung cancerliver cancermesotheliomasolid tumor
Beyond the preview
Go deeper on NCT06196294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196294.